Antibody-Based Therapy in Colorectal Cancer
Increasing new data reveal that antibody therapy induces antitumor activity, not only through direct blocking of vital signals provided by the target molecules, but also through stimulating ADCC and CDC activity. Thus, there will be a focus on antibody-engineering methods of how to maximize these responses in patients with CRC. In addition, mAb therapy targeting immune checkpoints will become standard in the clinic. Finding combinations of such mAbs with other drugs to achieve long-lasting clinical responses will be another critical issue and will be explored in future clinical trials. Identifying biomarkers for predicting the effects of antibody therapy will be critical for developing better treatment strategies.
Future Perspective
Increasing new data reveal that antibody therapy induces antitumor activity, not only through direct blocking of vital signals provided by the target molecules, but also through stimulating ADCC and CDC activity. Thus, there will be a focus on antibody-engineering methods of how to maximize these responses in patients with CRC. In addition, mAb therapy targeting immune checkpoints will become standard in the clinic. Finding combinations of such mAbs with other drugs to achieve long-lasting clinical responses will be another critical issue and will be explored in future clinical trials. Identifying biomarkers for predicting the effects of antibody therapy will be critical for developing better treatment strategies.
Source...